The role of IRIC’s Medicinal Chemistry core facility is to design and synthesize new small molecules having biological activity and potential therapeutic efficacy. Its specific objective is to optimize the biological activity of so-called hit or lead compounds, identified by high-throughput screening or targeted chemical synthesis, based on thorough investigation of their structure-activity relationships.
The core facility is available to scientists interested in developing novel and specific molecular tools which are used to facilitate the understanding of novel, therapeutically relevant biological targets, as well as offering support in the discovery of small molecules with therapeutic potential. In the framework of collaborative agreements with pharmaceutical companies, it also offers industrial partners an integrated research strategy encompassing several stages of the drug discovery process, from optimization of hit or lead compounds to identification of clinical candidates.
Medicinal Chemistry activities are directed by a team of seasoned chemists and biologists who have extensive drug-discovery experience in an industrial setting, demonstrated by a portfolio of significant achievements across several major therapeutic areas. The expertise of these scientists with background in the pharmaceutical industry is an important asset in adding value to projects aimed at discovering new drugs for the treatment of cancer and other unmet medical needs.